Investigators at UAB and colleagues at other universities have launched a study of a new, low-strength magnetic field as a potential therapy for depression.
Investigators studying a long-acting injectable formulation of aripiprazole, a partial dopamine agonist.
Yogesh Dwivedi, Ph.D., will join UAB in August as a professor and director of translational neuroscience in the Mood Disorders Program.
Researchers say ketamine appears to work on depression by blocking the neurotransmitter glutamate from binding to the NMDA receptor on neurons.
James Meador-Woodruff, M.D., chair of the Department of Psychiatry, was recently honored for mentoring researchers.